Condition
Neurogenic Inflammation
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06606236Not ApplicableCompletedPrimary
Neuropeptide Y Regulates Neurogenic Pulp Inflammation
NCT05411900Phase 2Unknown
BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome
NCT03663140CompletedPrimary
Neurogenic Inflammation in Peri-implant and Periodontal Diseases
NCT01881646Phase 4Completed
Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery
Showing all 4 trials